Logo image
Back
Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD
Journal article   Peer reviewed

Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD

L.J.A. D'Orsogna, D.L. Roelen, I.I.N. Doxiadis and F.H.J. Claas
Transplant Immunology, Vol.24(3)
2011
DOI: https://doi.org/10.1016/j.trim.2010.12.001
url
Link to Published Version *Subscription may be requiredView

Abstract

Immune deficiency and subsequent viral infection or reactivation is a common problem, particularly after stem cell transplantation. Virus specific T-cell adoptive immunotherapy across HLA barriers is increasingly being utilized as a treatment modality in immunocompromised patients. However, it was recently shown that nearly all viral specific memory T-cells are also allo-HLA reactive [1]. At least 45% of virus specific T-cell clones and most T-cell lines were shown to specifically crossreact against allogeneic HLA molecules. The allogeneic crossreactivity of CD8 and CD4 T-cells is directed primarily against HLA class I and II respectively [1–7], however, 3 viral specific CD8 T-cell clones have also been reported to exhibit allogeneic HLA class II crossreactivity [1,8]. As a consequence CD8 and CD4 T-cell adoptive immunotherapy across HLA barriers may be complicated by graft vs host disease (GvHD).

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

27 Record Views
8 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.6 Immunology
1.6.127 T Cell Regulation
Web Of Science research areas
Immunology
Transplantation
ESI research areas
Immunology
Logo image